In short
Clinical trials are investigating Solrikitug in adults with eosinophilic esophagitis, a condition that causes inflammation in the esophagus and trouble swallowing. These studies are looking at whether Solrikitug can improve signs of disease and how safe and tolerable it is over time.
Key points
- Clinical trials are studying Solrikitug in adults with eosinophilic esophagitis. The main goal is to see whether it can improve tissue inflammation and swallowing symptoms, while also checking safety and tolerability. The study is a Phase 2 trial and includes 180 participants. Part A compares Solrikitug with placebo, and Part B looks at longer-term safety. Researchers are measuring biopsy results, symptom scores, lab tests, vital signs, ECG results, and injection site tolerability.
Trial overview
The clinical trial NCT06598462 is an interventional Phase 2 study of Solrikitug in adults with eosinophilic esophagitis (EoE). The study is authorised and plans to enroll 180 participants.
This trial is designed to look at both efficacy (whether the treatment helps) and safety (whether it can be used safely in the study setting).
Who can participate
The trial is for adults with eosinophilic esophagitis. The source data do not list more detailed eligibility rules, so the exact age limits, symptom requirements, and other entry criteria are not provided here.
Because the study compares Solrikitug with placebo in Part A, some participants will receive the study drug and some will receive a matching placebo. A placebo is a look-alike treatment that does not contain the active study medicine.
What is being measured
In Part A, researchers are checking whether Solrikitug lowers the peak eosinophil count in biopsy samples to 6 or fewer eosinophils per high-power field at Week 24. Eosinophils are a type of white blood cell, and a high count in the esophagus can show inflammation.
They are also measuring the change in the DSQ total score from baseline to Week 24. The DSQ is a symptom score for swallowing problems, so a change in this score helps show whether dysphagia is improving or worsening.
In Part B, the study focuses on long-term safety and tolerability. The main safety outcomes include the incidence and severity of treatment-emergent adverse events (new medical problems that happen during the study), laboratory evaluations, vital signs, 12-lead ECG results, and injection site tolerability.
Study parts and design
The study has two parts. Part A compares Solrikitug with placebo to assess effects on tissue inflammation and dysphagia symptoms.
Part B looks at longer-term safety and tolerability of Solrikitug. The trial uses a subcutaneous injection form of Solrikitug at 500 mg, as listed in the study data.
What this means for patients
For adults living with eosinophilic esophagitis, this study is trying to answer two main questions: does Solrikitug improve signs of disease, and is it safe enough for longer use in the study setting?
The trial is not a completed treatment guide; it is a research study meant to collect evidence about outcomes that matter to patients, such as swallowing symptoms, tissue inflammation, and safety checks.